



ESMO 2014 Industry Satellite Symposium

Optimizing Treatment  
Benefits With MKIs:

# Understanding Who and When to Treat

Sunday 28 September 2014  
18:00-20:00

Granada Auditorium  
IFEMA  
Madrid, Spain

A meal will be provided.



# Optimizing Treatment Benefits With MKIs: Understanding Who and When to Treat

## Agenda

- |             |   |
|-------------|---|
| 18:00-18:15 | <b>Introduction</b><br><b>José Baselga (<i>Chair</i>)</b><br>Memorial Sloan-Kettering Cancer Center<br>New York, NY, United States  |
| 18:15-18:40 | <b>The RAI-Refractory DTC Patient: Optimizing Clinical Benefit</b><br><b>Martin Schlumberger</b><br>Gustave Roussy<br>Université Paris-Sud<br>Villejuif, France   |
| 18:40-19:05 | <b>Optimizing Patient Experience and Clinical Outcomes<br/>With Systemic Therapy in RAI-Refractory DTC</b><br><b>Marcia Brose</b><br>University of Pennsylvania<br>Abramson Cancer Center<br>Philadelphia, PA, United States                    |
| 19:05-19:40 | <b>Treatment Decisions in Unresectable HCC: Mapping<br/>Current Challenges and Emerging Opportunities</b><br><b>Jordi Bruix</b><br>Barcelona Clinic Liver Cancer (BCLC) Group<br>Hospital Clinic<br>University of Barcelona<br>Barcelona, Spain |
| 19:40-20:00 | <b>Concluding Remarks and Q&amp;A</b><br><b>José Baselga</b>  |



Bayer HealthCare

Bayer Pharma AG  
13342 Berlin, Germany  
[www.bayerpharma.com](http://www.bayerpharma.com)